search
Back to results

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

Primary Purpose

Fragile X Syndrome, Autism

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CX516 (Ampalex®)
Sponsored by
RespireRx
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fragile X Syndrome focused on measuring Fragile X Syndrome, Autism

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Fragile X group DNA-based diagnosis of Fragile X syndrome Autism group Documented diagnosis with ADOS; ADI-R; CARS and GARS Both groups 18-50 years Measured IQ below 85 Measured IQ >20 Mental age >30 months Stable medication regimen for past 8 weeks Normal hearing Vision corrected to at least 20/50 All females of childbearing age must have a negative pregnancy test at enrollment Exclusion criteria: Recent history of seizure, epilepsy, or blackouts Unresolved medical issue impacting performance Behavioral dysfunction to the point that subject cannot cooperate for testing History of drug-induced neutropenia Uncontrolled hypertension

Sites / Locations

  • UC Davis-MIND Institute
  • RUSH-Presbyterian-St. Luke's Medical Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
February 7, 2003
Last Updated
June 23, 2005
Sponsor
RespireRx
Collaborators
FRAXA Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00054730
Brief Title
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
Official Title
Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism
Study Type
Interventional

2. Study Status

Record Verification Date
February 2005
Overall Recruitment Status
Completed
Study Start Date
June 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
RespireRx
Collaborators
FRAXA Research Foundation

4. Oversight

5. Study Description

Brief Summary
This study will investigate whether CX516 can improve attention, memory, language, or behavior in adults with Fragile X Syndrome and/or Autism. CX516 is an AMPAKINE® compound. AMPAKINE compounds enhance synaptic strength. There is evidence to suggest that the synapses in the brain of an individual with fragile X syndrome are immature and abnormal. It is possible CX516 may partially correct this synaptic transmission defect and lead to improvement in cognitive and behavioral functioning. There is also reason to believe that these changes caused by CX516 could be helpful in managing cognitive and behavioral symptoms in patients with autistic disorder. Involvement for each participant will last 28 days. Participants will be given study medication, a physical exam, and a variety of cognitive assessment tests to study potential drug effectiveness at improving disease symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fragile X Syndrome, Autism
Keywords
Fragile X Syndrome, Autism

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
CX516 (Ampalex®)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Fragile X group DNA-based diagnosis of Fragile X syndrome Autism group Documented diagnosis with ADOS; ADI-R; CARS and GARS Both groups 18-50 years Measured IQ below 85 Measured IQ >20 Mental age >30 months Stable medication regimen for past 8 weeks Normal hearing Vision corrected to at least 20/50 All females of childbearing age must have a negative pregnancy test at enrollment Exclusion criteria: Recent history of seizure, epilepsy, or blackouts Unresolved medical issue impacting performance Behavioral dysfunction to the point that subject cannot cooperate for testing History of drug-induced neutropenia Uncontrolled hypertension
Facility Information:
Facility Name
UC Davis-MIND Institute
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
RUSH-Presbyterian-St. Luke's Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.fraxa.org
Description
Fraxa is a research foundation whose mission is to support research aimed at treatment for Fragile X syndrome.

Learn more about this trial

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

We'll reach out to this number within 24 hrs